ESMO 2018 | Denosumab for NSCLC: results from SPLENDOUR
Solange Peters
Speaking from the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, Solange Peters, MD, PhD, of University Hospital Vaudois, Lausanne, Switzerland, gives us an update on the ETOP and EORTC SPLENDOUR trial (NCT02129699) of denosumab for advanced non-small cell lung cancer.
Related videos
10:18 Impact and learnings from the COVID-19 pandemic
Riyaz Shah
3:04 NSCLC highlights at ASCO 2020
Riyaz Shah
1:42 Horizon scanning in lung cancer
Sanjay Popat
0:00 Checkpoint inhibitors in the treatment of thoracic malignancies
Sanjay Popat
4:18 Changing management of thoracic malignancies as a result of the COVID-19 pandemic
Sanjay Popat
